Pharmacological management of human respiratory syncytial virus infection-Reference-Cited by-同舟云学术

Pharmacological management of human respiratory syncytial virus infection

Published:2020-08-18 Issue:18 Volume:21 Page:2293-2303
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Kalergis Alexis M.¹²^ORCID,Soto Jorge A.¹,Gálvez Nicolás M. S.¹^ORCID,Andrade Catalina A.¹,Fernandez Ayleen¹,Bohmwald Karen¹,Bueno Susan M.¹^ORCID

Affiliation:

1. Millennium Institute on Immunology and Immunotherapy, Departamento De Genética Molecular Y Microbiología, Facultad De Ciencias Biológicas, Pontificia Universidad Católica De Chile, Santiago, Chile

2. Departamento De Endocrinología, Facultad De Medicina, Pontificia Universidad Católica De Chile, Santiago, Chile

Funder

Millennium Institute on Immunology and Immunotherapy from Chile

Biomedical Research Consortium

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1806821

Reference150 articles.

1. Viruses exacerbating chronic pulmonary disease: the role of immune modulation

2. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis

3. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain

4. The significance of human respiratory syncytial virus (HRSV) in children from Ghana with acute lower respiratory tract infection: A molecular epidemiological analysis, 2006 and 2013-2014

5. Taxonomy of the order Mononegavirales: update 2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A molecular perspective for the development of antibodies against the human respiratory syncytial virus;Antiviral Research;2024-02

2. New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus;Infection and Drug Resistance;2023-04

3. Respiratory Syncytial Virus Infection: Treatments and Clinical Management;Vaccines;2023-02-20

4. LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections;Viruses;2023-01-03

5. Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies;Infection and Drug Resistance;2023-01